Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

NCT07500987 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutation-positive NSCLC

Interventions

DRUG: [111In]-FPI-2107
DRUG: FPI-2053

Sponsor

AstraZeneca